PET/TC-PSMA en cáncer de próstata: perfil de pacientes en la vida real: Experiencia del Instituto Alexander Fleming

Martín Zarbá; Federico Losco; Silvina Racioppi; Martina Musumeci; Mauro Orlando; Martín Ángel; Juan Pablo Sade; Matías Chacón

doi:10.56969/oc.v27i1.3

Autores/as

Martín Zarbá Instituto Alexander Fleming, Buenos Aires
Federico Losco Instituto Alexander Fleming, Buenos Aires https://orcid.org/0000-0001-5084-3012
Silvina Racioppi Instituto Alexander Fleming, Buenos Aires https://orcid.org/0000-0001-6206-1042
Martina Musumeci Instituto Alexander Fleming, Buenos Aires
Mauro Orlando Instituto Alexander Fleming, Buenos Aires
Martín Ángel Instituto Alexander Fleming, Buenos Aires https://orcid.org/0000-0002-1463-8887
Juan Pablo Sade Instituto Alexander Fleming, Buenos Aires
Matías Chacón Instituto Alexander Flemming, Buenos Aires https://orcid.org/0000-0002-4935-9773

DOI:

https://doi.org/10.56969/oc.v27i1.3

Palabras clave:

PET-TC-PSMA, cáncer de próstata, recaída bioquímica, terapia dirigida a la metástasis, PSMA PET-CT, prostate cancer, biochemical recurrence, metastasis directed therapy

Resumen

El PET/TC-PSMA es una técnica de imagen no invasiva que demostró ser más sensible y específica comparado con el PET-Colina, sobre todo con valores de PSA <1 ng/ml. Últimamente su utilización ha ganado terreno y tiene indicaciones precisas en enfermedad localizada de alto riesgo y en recaída bioquímica.

Los objetivos del presente estudio fueron identificar las indicaciones del PET/TC PSMA y evaluar el impacto del resultado del estudio en la indicación de terapia dirigida a la metástasis.

Se trata de un estudio descriptivo, observacional, retrospectivo y mono institucional.

Se incluyeron todos los pacientes con diagnóstico de cáncer de próstata que realizaron 68Ga-PSMA- PET/TC en el Instituto Alexander Fleming (IAF) y se excluyeron a aquellos que no tuvieron seguimiento en esta institución.

Se obtuvieron los resultados de 39 PET/TC-PSMA. Los motivos de indicación de dichos estudios fueron la recaída bioquímica en 24 pacientes (61.5%), el diagnóstico de enfermedad localizada de alto riesgo en 8 (20.5%) y otras indicaciones en 7 (18%).

Se evidenció captación patológica en todos los PET/ TC-PSMA realizados con un valor de PSA ≥ 0.71 ng/ ml y en 2 con valores menores (con 0.06 y 0.4 ng/ml).

De los 24 pacientes que realizaron el estudio por recaída bioquímica, a 9 (37.5%) se les realizó tratamiento dirigido a la metástasis (7 SBRT y 2 linfadenectomias).

En nuestra institución, la mayoría de las indicaciones del PET/TC PSMA se realizaron en coincidencia con las recomendaciones actuales de enfermedad localizada de alto riesgo y en recaída o persistencia bioquímica.

Citas

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7-30. DOI: https://doi.org/10.3322/caac.21387

Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer, version 1.2016. J Natl Compr Canc Netw 2016; 14:19- 30. DOI: https://doi.org/10.6004/jnccn.2016.0186

Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71: 618-29. DOI: https://doi.org/10.1016/j.eururo.2016.08.003

Suardi N, Porter CR, Reuther AM, et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer 2008; 112: 1254-63. DOI: https://doi.org/10.1002/cncr.23293

Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004; 172: 910-4. DOI: https://doi.org/10.1097/01.ju.0000134888.22332.bb

Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006; 176: 1415-9. DOI: https://doi.org/10.1016/j.juro.2006.06.002

Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001; 166: 876-81. DOI: https://doi.org/10.1016/S0022-5347(05)65855-7

Einspieler I, Rauscher I, Düwel C, et al. Detection efficacy of hybrid 68Ga-PSMA ligand PET/CT in prostate cancer patients with biochemical recurrence after primary radiation therapy defined by Phoenix Criteria. J Nucl Med 2017; 58:1081-7. DOI: https://doi.org/10.2967/jnumed.116.184457

Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 197-209. DOI: https://doi.org/10.1007/s00259-014-2949-6

Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25: 2035-41. DOI: https://doi.org/10.1200/JCO.2006.08.9607

Stish BJ, Pisansky TM, Harmsen WS, et al. Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer. J Clin Oncol 2016; 34: 3864-71. DOI: https://doi.org/10.1200/JCO.2016.68.3425

Vinsensia M, Chyoke PL, Hadaschik B, et al. 68Ga-PSMA PET/CT and volumetric morphology of PET-positive lymph nodes stratified by tumor differentiation of prostate cancer. J Nucl Med 2017; 58: 1949-55. DOI: https://doi.org/10.2967/jnumed.116.185033

Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of Hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2015; 56: 668-74 DOI: https://doi.org/10.2967/jnumed.115.154153

Uprimny C, Kroiss AS, Fritz J, Decristoforo C, Kendler D, von Guggenberg E, et al. Early PET imaging with [68] Ga- PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence. Eur J Nucl Med Mol Imaging 2017; 44: 1647-55.

Kroiss AS, Fritz J, Decristoforo C, et al. Early PET imaging with [68] Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence. Eur J Nucl Med Mol Imaging 2017; 44: 1647-55. DOI: https://doi.org/10.1007/s00259-017-3743-z

Rauscher I, Maurer T, Beer AJ, et al. Value of 68Ga- PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cáncer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J Nucl Med 2016; 57: 1713-9.

Afshar-Oromieh A, Holland-Letz T, Giesel FL, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/ CT in patients with recur- rent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging 2017; 44: 1258-

M, Maurer T, Gschwend J, et al. Patterns of failure after radical prostatectomy in prostate cancer - implications for radiation therapy planning after 68Ga-PSMA-PET imaging. Eur J Nucl Med Mol Imaging 2017; 44: 1656-62. DOI: https://doi.org/10.1007/s00259-017-3746-9

Rauscher I, Maurer T, Beer AJ, et al. Value of 68Ga- PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cáncer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J Nucl Med 2016; 57: 1713-9. DOI: https://doi.org/10.2967/jnumed.116.173492

Morigi JJ, Stricker PD, van Leeuwen PJ, et al. Prospective comparison of 18F-fluoro- methylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 2015; 56: 1185-90. DOI: https://doi.org/10.2967/jnumed.115.160382

Umbehr MH, Müntener M, Hany T, Sulser T, Bachmann LM. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol 2013; 64: 106-17. DOI: https://doi.org/10.1016/j.eururo.2013.04.019

Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analisis. Eur Urol 2016; 70: 926-37. DOI: https://doi.org/10.1016/j.eururo.2016.06.021

Afshar-Oromieh A, Holland-Letz T, Giesel FL, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/ CT in patients with recur- rent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging 2017; 44:1258-68. DOI: https://doi.org/10.1007/s00259-017-3711-7

Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41: 11-20. DOI: https://doi.org/10.1007/s00259-013-2525-5

Bluemel C, Krebs M, Polat B, et al. 68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-Choline-PET/CT. Clin Nucl Med 2016; 41: 515-21. DOI: https://doi.org/10.1097/RLU.0000000000001197

Prostate cancer - Guidelines. En: https://uroweb.org/ guideline/prostate-cáncer; consultado septiembre 2021.

Federatie Medisch Specialisten. Prostaatcarcinoom. En: https://richtlijnendatabase.nl/richtlijn/prostaatcarcinoom/ diagnostiek/beeldvormend_onderzoek/psma_pet_ct_bij_ prostaatcarcinoom.html; consultado septiembre 2021.